OTX-TIC (travoprost insert)
Glaucoma / Ocular Hypertension
Key Facts
About Ocular Therapeutix
Ocular Therapeutix is a commercial-stage biopharmaceutical company pioneering sustained-release therapies for ocular diseases through its proprietary bioresorbable hydrogel technology. Its mission is to improve patient outcomes by transforming the standard of care from frequent eye drops and injections to single-administration, long-lasting treatments. The company has achieved a significant milestone with the FDA approval and commercialization of DEXTENZA and is advancing a robust pipeline, including its most advanced candidate, OTX-TKI (axitinib implant) for wet AMD, which is in pivotal Phase 3 trials. Its strategic direction focuses on leveraging its platform to address major unmet needs in both the front and back of the eye.
View full company profileTherapeutic Areas
Other Glaucoma / Ocular Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| SE-1003 | Santen Pharmaceutical | Phase 2 |
| Tapros® (tafluprost) | Santen Pharmaceutical | Approved |
| Mirac® (ripasudil) | Santen Pharmaceutical | Approved |
| Catioprost® | Santen Pharmaceutical | Approved |
| Vyzulta (latanoprostene bunod) | Bausch Health | Approved |